Literature DB >> 21491912

Identification of immunoreactive regions of homology between soluble epidermal growth factor receptor and α5-integrin.

Jason A Wilken1, Andre T Baron, Ramsey A Foty, Daniel J McCormick, Nita J Maihle.   

Abstract

Proteins encoded by the epidermal growth factor receptor (EGFR/HER1/ERBB1) gene are being studied as diagnostic, prognostic, and theragnostic biomarkers for numerous human cancers. The clinical application of these tissue/tumor biomarkers has been limited, in part, by discordant results observed for epidermal growth factor receptor (EGFR) expression using different immunological reagents. Previous studies have used EGFR-directed antibodies that cannot distinguish between full-length and soluble EGFR (sEGFR) expression. We have generated and characterized an anti-sEGFR polyclonal antiserum directed against a 31-mer peptide (residues 604-634) located within the unique 78-amino acid carboxy-terminal sequence of sEGFR. Here, we use this antibody to demonstrate that sEGFR is coexpressed with EGFR in a number of carcinoma-derived cell lines. In addition, we show that a second protein of ~140 kDa (p140) also is detected by this antibody. Rigorous biochemical characterization identifies this second protein to be α5-integrin. We show that a 26-amino acid peptide in the calf domain of α5-integrin (residues 710-735) is 35% identical in sequence with a 31-mer carboxy-terminal sEGFR peptide and exhibits an approximately 5-fold lower affinity for anti-sEGFR than the homologous 31-mer sEGFR peptide does. We conclude that the carboxy terminus of sEGFR and the calf-1 domain of α5-integrin share a region of sequence identity, which results in their mutual immunological reactivity with anti-sEGFR. We also demonstrate that anti-sEGFR promotes three-dimensional tissue cohesion and compaction in vitro, further suggesting a functional link between sEGFR and α5-integrin and a role of the calf-1 domain in cell adhesion. These results have implications for the study of both EGFR and sEGFR as cancer biomarkers and also provide new insight into the mechanisms of interaction between cell surface EGFR isoforms and integrins in complex processes such as cell adhesion and survival signaling.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21491912      PMCID: PMC3862712          DOI: 10.1021/bi200126j

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  35 in total

1.  Covalent cross-linking of fibronectin to fibrin is required for maximal cell adhesion to a fibronectin-fibrin matrix.

Authors:  S A Corbett; L Lee; C L Wilson; J E Schwarzbauer
Journal:  J Biol Chem       Date:  1997-10-03       Impact factor: 5.157

2.  The BASP1 family of myristoylated proteins abundant in axonal termini. Primary structure analysis and physico-chemical properties.

Authors:  M I Mosevitsky; J P Capony; V A Novitskaya; V V Zakharov
Journal:  Biochimie       Date:  1997-06       Impact factor: 4.079

3.  Optimal alignments in linear space.

Authors:  E W Myers; W Miller
Journal:  Comput Appl Biosci       Date:  1988-03

4.  Serum soluble epidermal growth factor receptor concentrations decrease in postmenopausal metastatic breast cancer patients treated with letrozole.

Authors:  Jacqueline M Lafky; Andre T Baron; Elsa M Cora; David W Hillman; Vera J Suman; Edith A Perez; James N Ingle; Nita J Maihle
Journal:  Cancer Res       Date:  2005-04-15       Impact factor: 12.701

5.  Two antigenically related neuronal cell adhesion molecules of different specificities mediate neuron-neuron and neuron-glia adhesion.

Authors:  M Grumet; S Hoffman; G M Edelman
Journal:  Proc Natl Acad Sci U S A       Date:  1984-01       Impact factor: 11.205

6.  The epidermal growth factor receptor conundrum.

Authors:  Jason A Wilken; Andre T Baron; Nita J Maihle
Journal:  Cancer       Date:  2010-12-14       Impact factor: 6.860

7.  Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target.

Authors:  Kenjiro Sawada; Anirban K Mitra; A Reza Radjabi; Vinay Bhaskar; Emily O Kistner; Maria Tretiakova; Sujatha Jagadeeswaran; Anthony Montag; Amy Becker; Hilary A Kenny; Marcus E Peter; Vanitha Ramakrishnan; S Diane Yamada; Ernst Lengyel
Journal:  Cancer Res       Date:  2008-04-01       Impact factor: 12.701

8.  An N-glycosylation site on the beta-propeller domain of the integrin alpha5 subunit plays key roles in both its function and site-specific modification by beta1,4-N-acetylglucosaminyltransferase III.

Authors:  Yuya Sato; Tomoya Isaji; Michiko Tajiri; Shumi Yoshida-Yamamoto; Tsuyoshi Yoshinaka; Toshiaki Somehara; Tomohiko Fukuda; Yoshinao Wada; Jianguo Gu
Journal:  J Biol Chem       Date:  2009-03-09       Impact factor: 5.157

Review 9.  Clinical implementation of soluble EGFR (sEGFR) as a theragnostic serum biomarker of breast, lung and ovarian cancer.

Authors:  Andre T Baron; Jason A Wilken; Daniel E Haggstrom; Scott T Goodrich; Nita J Maihle
Journal:  IDrugs       Date:  2009-05

10.  Isolation and characterization of Chinese hamster ovary cell variants deficient in the expression of fibronectin receptor.

Authors:  C L Schreiner; J S Bauer; Y N Danilov; S Hussein; M M Sczekan; R L Juliano
Journal:  J Cell Biol       Date:  1989-12       Impact factor: 10.539

View more
  5 in total

1.  A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study.

Authors:  Kimberly K Leslie; Michael W Sill; Edgar Fischer; Kathleen M Darcy; Robert S Mannel; Krishnansu S Tewari; Parviz Hanjani; Jason A Wilken; Andre T Baron; Andrew K Godwin; Russell J Schilder; Meenakshi Singh; Nita J Maihle
Journal:  Gynecol Oncol       Date:  2013-02-21       Impact factor: 5.482

Review 2.  EGFR/HER-targeted therapeutics in ovarian cancer.

Authors:  Jason A Wilken; Tayf Badri; Sarah Cross; Rhoda Raji; Alessandro D Santin; Peter Schwartz; Adam J Branscum; Andre T Baron; Adam I Sakhitab; Nita J Maihle
Journal:  Future Med Chem       Date:  2012-03       Impact factor: 3.808

3.  Multiplex epitope mapping using bacterial surface display reveals both linear and conformational epitopes.

Authors:  Elton P Hudson; Mathias Uhlen; Johan Rockberg
Journal:  Sci Rep       Date:  2012-10-04       Impact factor: 4.379

4.  EGFR soluble isoforms and their transcripts are expressed in meningiomas.

Authors:  Angélique Guillaudeau; Karine Durand; Barbara Bessette; Alain Chaunavel; Isabelle Pommepuy; Fabrice Projetti; Sandrine Robert; François Caire; Hélène Rabinovitch-Chable; François Labrousse
Journal:  PLoS One       Date:  2012-05-18       Impact factor: 3.240

5.  Expression of EGFR isoform D is regulated by HER receptor activators in breast cancer cells.

Authors:  Lisandra Negrón-Vega; Elsa M Cora; Marianela Pérez-Torres; Shou-Ching Tang; Nita J Maihle; Jung Su Ryu
Journal:  Biochem Biophys Rep       Date:  2022-08-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.